TSCAN THERAPEUTICS, INC.
Ownership & governance
Executives 5Directors 7Avg age 61Avg tenure 2.9y
GM
Gavin MacBeath
Chief Executive Officer
Age 56Since 2023-03-27Profile →
+11
Executives5
GM
Gavin MacBeath→
Chief Executive Officer
Age 56Since 2023-03-27
JA
Jason Amello→
Director of Finance/CFO
Age 57Since 2024-01-28
DP
Dawn Pinchasik→
Chief Tech/Sci/R&D Officer
—Since 2024-02-05
CL
Chrystal Louis→
Chief Tech/Sci/R&D Officer
Age 50Since 2024-04-07
SC
Shrikanta Chattopadhya→
Chief Tech/Sci/R&D Officer
——
Board of directors7
KD
Katina Dorton→
Director/Board Member
Age 68Since 2021-03-22
GM
Gavin MacBeath→
Director/Board Member
Age 56Since 2023-05-23
SB
Stephen Biggar→
Chairman
Age 55Since 2024-06-11
GG
Gabriela Gruia→
Director/Board Member
Age 69Since 2021-05-26
BK
Barbara Klencke→
Director/Board Member
Age 68Since 2023-04-05
RW
Robert Woods→
Director/Board Member
Age 58Since 2023-12-05
GN
Garry Nicholson→
Director/Board Member
Age 71Since 2024-06-13
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Lynx1 Capital Management LP | 13.13 % | 8,019,148 |
| BVF, Inc. | 9.111 % | 5,564,290 |
| K2 Healthventures Equity Trust LLC | 5.899 % | 3,602,700 |
| Baker Bros. Advisors LP | 4.56 % | 2,784,792 |
| Baker Bros. Advisors LP | 4.56 % | 2,784,792 |
Catalog · 2026-07-09
Registry officers12
| Name | Role | Since | Shares |
|---|---|---|---|
| Chrystal Louis | Chief Tech/Sci/R&D Officer | 2024-04-07 | - |
| Dawn Pinchasik | Chief Tech/Sci/R&D Officer | 2024-02-05 | - |
| Gavin MacBeath | Chief Executive Officer | 2023-03-27 | - |
| Jason Amello | Director of Finance/CFO | 2024-01-28 | - |
| Shrikanta Chattopadhya | Chief Tech/Sci/R&D Officer | — | - |
| Stephen Biggar | Chairman | 2024-06-11 | - |
| Barbara Klencke | Director/Board Member | 2023-04-05 | - |
| Gabriela Gruia | Director/Board Member | 2021-05-26 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus holdMean target 1Range 1–1Analysts 2
- Buy 1
- Hold 4
Broker actions40 of 41
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Downgrade | Neutral | 1 | 2026-09-08 |
| Wedbush | Downgrade | Neutral | 1 | 2026-09-03 |
| Needham | Downgrade | Hold | — | 2026-09-02 |
| HC Wainwright & Co. | Reiterated | Buy | 7 | 2026-08-12 |
| Wedbush | Reiterated | Outperform | 5 | 2026-06-23 |
| Needham | Reiterated | Buy | 6 | 2026-06-23 |
| Wedbush | Maintained | Outperform | 5 | 2026-03-05 |
| HC Wainwright & Co. | Maintained | Buy | 7 | 2025-11-13 |
| BTIG | Downgrade | Neutral | — | 2025-11-04 |
| Needham | Maintained | Buy | 6 | 2025-11-04 |
| HC Wainwright & Co. | Maintained | Buy | 10 | 2025-05-07 |
| Needham | Reiterated | Buy | 9 | 2025-04-08 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.